Date: June 22, 2026
Strategic Initiative: BIO International Convention Participation
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, announced its participation in the BIO International Convention 2026 (BIO-2026), one of the world's largest Biotechnology Partnering Conferences, taking place from June 22–25, 2026, in San Diego, USA.
The primary objective is to showcase the company's differentiated Central Nervous System (CNS) clinical portfolio to delegates, investors, and potential partners from big pharma and biotech companies at Booth #6154. The strategic goal is to engage in 62 pre-scheduled partnering meetings over the 4-day event to explore out-licensing and/or co-development initiatives for its clinical candidates.
Clinical Pipeline Overview and Progress
Suven's portfolio targets significant unmet medical needs in CNS disorders. The company owns all intellectual property rights for its assets in all major markets.
Key Clinical Candidates:
Ropanicant (SUVN-911)
- Mechanism: α4β2 receptor antagonist
- Indication: Major Depressive Disorder (MDD)
- Differentiation: Novel antidepressant candidate offering rapid onset of efficacy, pro-cognitive effects, and a favourable sexual side-effect profile.
- Status: Positive topline results from a Phase-2b clinical Proof-of-Concept trial were announced on June 17, 2026. This builds on promising safety and efficacy from a positive Phase-2a open-label study.
- Next Steps: A global Phase-3 study is planned to start in H1-2027.
Masupirdine (SUVN-502)
- Mechanism: 5-HT6 Receptor antagonist
- Indication: Agitation in Dementia of Alzheimer's Type
- Differentiation: Novel, nondopaminergic, non-sedative approach aimed at transforming Alzheimer's agitation management, with a dual impact on behavioral stabilization and cognition.
- Status: Global Phase-3 study (AWAKE study) is in progress and is 95% enrolled.
- Timeline: Topline results are expected in Q2-2027.
Samelisant (SUVN-G3031)
- Mechanism: Non-controlled, non-stimulant H3 inverse agonist
- Indication: Excessive Daytime Sleepiness (EDS) in Narcolepsy
- Differentiation: Designed to deliver wake-promoting efficacy with a differentiated safety edge, offering a cleaner drug-drug interaction and cardiovascular profile versus the current standard of therapy.
- Status: A global Phase-3 study has been initiated.
- Timeline: Topline results are expected in Q2-2028.
Usmarapride (SUVN-D4010)
- Mechanism: 5-HT4 Receptor Partial Agonist
- Indication: Potential treatment of cognitive disorders
- Status: Was safe and well tolerated with dose-dependent pharmacokinetics in a Phase-1 study.
- Next Steps: A Phase-2 study is planned.
SUVN-I6107
- Mechanism: Muscarinic M1 true positive allosteric modulator (PAM)
- Indication: Potential treatment of cognitive disorders
- Status: Demonstrated favourable pharmacokinetics, safety, and tolerability profile (with no cholinergic adverse events) in a recently completed Phase-1 trial. Pharmacodynamic outcomes indicated enhanced alertness and information processing.
- Next Steps: A Phase-2 study is in the planning stage.
Management Commentary
Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences, stated: "BIO-2026 offers a valuable opportunity to highlight the meaningful advancements across our clinical pipeline and connect with potential partners who share our dedication to addressing unmet needs in CNS disorders. The positive Phase 2b results for Ropanicant in major depressive disorder, promising and favourable Phase-1 data for SUVN-I6107, continued progress of our Phase-3 programs, Masupirdine for agitation in dementia of Alzheimer's type and Samelisant (AWAKE study) for narcolepsy, underscore the depth and maturity of our portfolio. We look forward to exploring strategic partnering and collaboration opportunities that can help accelerate the development and commercialization of these assets."
Delegation Details
The Suven delegation attending BIO-2026 includes senior leaders from management and research:
- Venkat Jasti, Chairman and Managing Director
- Ramakrishna Nirogi, President and Chief Scientific Officer
- Anil Shinde, Vice President, Drug Chemistry
- Pradeep Jayarajan, Vice President, Drug Biology
- Vijay Benade, Associate Vice President, Drug Metabolism & Pharmacokinetics
- Satish Jetta, Associate Vice President, Quality Assurance & Regulatory